Arrowgrass Capital Partners (US)’s Allergan plc AGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-73,200
Closed -$12M 524
2017
Q4
$12M Buy
73,200
+72,419
+9,273% +$13M 0.12% 205
2017
Q3
$16M Sell
781
-290
-27% -$67.4K 0.12% 211
2017
Q2
$26M Buy
1,071
+330
+45% +$77.5K 0.2% 137
2017
Q1
$17.7M Buy
741
+356
+92% +$82.9K 0.18% 159
2016
Q4
$8.09M Buy
385
+155
+67% +$32.1K 0.09% 214
2016
Q3
$5.3M Buy
+230
New +$56.2K 0.07% 203
2016
Q1
Sell
-55
Closed -$1.72M 473
2015
Q4
$1.72M Hold
55
0.02% 264
2015
Q3
$1.5M Buy
+55
New +$16.9K 0.03% 296

Other funds holding AGN

Arrowgrass Capital Partners (US)'s AGN Position: Q3 2019 in Review

Arrowgrass Capital Partners (US) sold out of Allergan plc (AGN) in Q3 2019, closing a stake of 405,630 shares — an estimated $67.9M sold.

Arrowgrass Capital Partners (US) first reported a position in AGN in Q2 2013 and held it in 13 quarters. The position peaked at $282M in Q1 2016. 921 funds tracked by Wall St. Rank hold AGN as of Q3 2019.

  • Arrowgrass Capital Partners (US) reported no remaining Allergan plc position as of Q3 2019 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 405,630 Allergan plc shares in Q3 2019, an estimated $67.9M.
  • Arrowgrass Capital Partners (US) first reported a position in Allergan plc in Q2 2013 and held it in 13 quarters.
  • Arrowgrass Capital Partners (US)'s Allergan plc position peaked at $282M in Q1 2016.
  • 921 funds tracked by Wall St. Rank held Allergan plc as of Q3 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2019, filed 14 Nov 2019.